MARKET

NLTX

NLTX

Neoleukin Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.04
-0.39
-3.14%
After Hours: 12.04 0 0.00% 16:07 02/26 EST
OPEN
12.52
PREV CLOSE
12.43
HIGH
12.87
LOW
11.74
VOLUME
259.10K
TURNOVER
--
52 WEEK HIGH
18.13
52 WEEK LOW
5.81
MARKET CAP
504.41M
P/E (TTM)
-18.6032
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participa...
GlobeNewswire · 02/05 13:00
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Neoleukin Therapeutics, Inc. (NLTX) Investigation
ACCESSWIRE · 01/14 16:25
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Neoleukin Therapeutics, Inc. (NLTX) Investigation
ACCESSWIRE · 01/14 16:25
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Neoleukin Therapeutics, Inc. (NLTX) Investigation
ACCESSWIRE · 01/14 16:25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Neoleukin Therapeutics (NLTX) and NovoCure (NVCR)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Neoleukin Therapeutics (NLTX) and NovoCure (NVCR).
SmarterAnalyst · 01/11 13:17
Jaguar Health and Chimerix among healthcare gainers; Sarepta Therapeutics leads losers
Gainers: Chimerix (CMRX) +59%. Jaguar Health (JAGX) +36%. Medigus (MDGS) +23%. Merus (MRUS) +22%. SCWorx (WORX) +20%.Losers: Sarepta Therapeutics (SRPT) -50%. SOS (SOS) -42%. Neoleukin Therapeutics (NLTX) -15%. Bionano Genomics (BNGO) -14%.
Seekingalpha · 01/08 16:00
Aquinox (NLTX) Moves to Buy: Rationale Behind the Upgrade
Zacks.com · 01/08 15:54
U.S. FDA puts early-stage trial of Neoleukin potential cancer treatment on hold
Neoleukin Therapeutics Inc said on Friday the U.S. Food and Drug Administration has put on hold the drug developer's application to start human trials of its protein-based candidate, NL-201, to treat cancer.
Reuters · 01/08 13:37
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NLTX. Analyze the recent business situations of Neoleukin Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NLTX stock price target is 22.13 with a high estimate of 30.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 126
Institutional Holdings: 27.87M
% Owned: 66.53%
Shares Outstanding: 41.89M
TypeInstitutionsShares
Increased
29
2.18M
New
32
-499.42K
Decreased
22
1.54M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Independent Director
Todd Simpson
President/Chief Executive Officer/Director
Jonathan Drachman
Chief Financial Officer/Secretary
Robert Ho
Vice President
Leslie Aberman
Vice President
Samantha Willing
General Counsel
Holly Vance
Director
Martin Babler
Director
Erin Lavelle
Independent Director
M. Cantey Boyd
Independent Director
Sarah Noonberg
Independent Director
Lewis Williams
  • Dividends
  • Splits
  • Insider Activity
No Data
About NLTX
Neoleukin Therapeutics, Inc., formerly Aquinox Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity. Its computational platform allows it to design new de novo proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its lead program, NL-201, is a computationally-designed de novo protein therapeutic. NL-201 is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities.

Webull offers kinds of Neoleukin Therapeutics Inc stock information, including NASDAQ:NLTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NLTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NLTX stock methods without spending real money on the virtual paper trading platform.